Bio-Thera Solutions Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Bio-Thera Solutions şirketinin toplam hissedar öz sermayesi CN¥847.3M ve toplam borcu CN¥702.0M olup, bu da borç-öz sermaye oranını 82.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥2.3B ve CN¥1.5B dir.

Anahtar bilgiler

82.8%

Borç/özkaynak oranı

CN¥701.97m

Borç

Faiz karşılama oranı	n/a
Nakit	CN¥451.10m
Eşitlik	CN¥847.30m
Toplam yükümlülükler	CN¥1.49b
Toplam varlıklar	CN¥2.34b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Optimistic Investors Push Bio-Thera Solutions, Ltd. (SHSE:688177) Shares Up 44% But Growth Is Lacking

Oct 09

Time To Worry? Analysts Just Downgraded Their Bio-Thera Solutions, Ltd. (SHSE:688177) Outlook

Sep 05

Bio-Thera Solutions, Ltd. (SHSE:688177) Shares May Have Slumped 30% But Getting In Cheap Is Still Unlikely

Jun 06

Some Confidence Is Lacking In Bio-Thera Solutions, Ltd. (SHSE:688177) As Shares Slide 27%

Apr 18

Subdued Growth No Barrier To Bio-Thera Solutions, Ltd. (SHSE:688177) With Shares Advancing 30%

Mar 04

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 688177 'nin kısa vadeli varlıkları ( CN¥1.0B ) kısa vadeli yükümlülüklerini ( CN¥1.1B ) kapsamıyor.

Uzun Vadeli Yükümlülükler: 688177 şirketinin kısa vadeli varlıkları ( CN¥1.0B ) uzun vadeli yükümlülüklerini ( CN¥410.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 688177 'nin net borç/öz sermaye oranı ( 29.6% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: 688177 şirketinin borç/öz sermaye oranı son 5 yılda 11.3% seviyesinden 82.8% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 688177 şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: 688177 tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Bio-Thera Solutions Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings released: CN¥0.31 loss per share (vs CN¥0.31 loss in 3Q 2023)

Optimistic Investors Push Bio-Thera Solutions, Ltd. (SHSE:688177) Shares Up 44% But Growth Is Lacking

Bio-Thera Solutions, Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Time To Worry? Analysts Just Downgraded Their Bio-Thera Solutions, Ltd. (SHSE:688177) Outlook

Second quarter 2024 earnings released: CN¥0.28 loss per share (vs CN¥0.27 loss in 2Q 2023)

European Medicines Agency (EMA) Approves Bio-Thera Solutions' BAT1706 (Avzivi, bevacizumab), A Biosimilar Referencing Avastin

Bio-Thera Solutions Initiates Integrated Phase I / Phase III Clinical Trial for BAT3306, A Proposed Biosimilar of Keytruda (Pembrolizumab)

Bio-Thera Solutions Announces Regulatory Filing Acceptance for BAT2206, A Proposed Biosimilar to Stelara in the US and EU

Bio-Thera Solutions, Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Bio-Thera Solutions, Ltd. (SHSE:688177) Shares May Have Slumped 30% But Getting In Cheap Is Still Unlikely

Bio-Thera Solutions Receives Positive CHMP Opinion for Avzivi (Bevacizumab), A Biosimilar Referencing Avastin

Price target decreased by 22% to CN¥42.10

First quarter 2024 earnings released: CN¥0.29 loss per share (vs CN¥0.34 loss in 1Q 2023)

Some Confidence Is Lacking In Bio-Thera Solutions, Ltd. (SHSE:688177) As Shares Slide 27%

Bio-Thera Solutions, Ltd., Annual General Meeting, Apr 18, 2024

Full year 2023 earnings released: CN¥0.95 loss per share (vs CN¥1.16 loss in FY 2022)

Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006

Subdued Growth No Barrier To Bio-Thera Solutions, Ltd. (SHSE:688177) With Shares Advancing 30%

Full year 2023 earnings released: CN¥0.97 loss per share (vs CN¥1.16 loss in FY 2022)

Bio-Thera Solutions Announces Initiation of Phase IB / IIA Clinical Trial for BAT6026

FDA Approves Bio-Thera Solutions' Avzivi (Bevacizumab-Tnjn), A Biosimilar Referencing Avastin

Bio-Thera Solutions Announces Positive Results from Phase 3 Study of BAT2206, a Proposed Biosimilar Referencing Stelara

Third quarter 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.21 loss in 3Q 2022)

Chugai Pharmaceutical Co., Ltd., Roche, Genentech, Biogen MA Inc. and Bio-Thera Solutions, Ltd. Withdraw Lawsuit

FDA Approves Bio-Thera Solutions, Ltd.'s Partner Biogen Receives Notification from the United States Food and Drug Administration

Second quarter 2023 earnings released: CN¥0.27 loss per share (vs CN¥0.14 loss in 2Q 2022)

Bio-Thera Solutions, Ltd. Announces Positive Phase 1 Clinical Data for Bat8006 (Folate-Receptor-A-Adc) and Presents Phase 1 Dose Escalation Study At the Bethune Obstetrics and Gynecology Forum

Chugai Files Patent Infringement Lawsuit Against Biogen MA Inc. and Bio-Thera Solutions, Ltd. in the U.S

First quarter 2023 earnings released: CN¥0.34 loss per share (vs CN¥0.27 loss in 1Q 2022)

China NMPA Approves Bio-Thera Solutions' BAT1806, A Biosimilar to Actemra(R) (Tocilizumab)

Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2306

Third quarter 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.28 loss in 3Q 2021)

Bio-Thera Solutions, Ltd. Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala (mepolizumab)

Second quarter 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.27 profit in 2Q 2021)

Bio-Thera Solutions, Ltd. Announces First Patient Dosed in Phase 1 Study for Bat8009, an Antibody Drug Conjugate Targeting B7-H3 (Cd276) for the Treatment of Advanced Solid Tumors

Bio-Thera Solutions, Ltd Announces First Patient Dosed in Phase 1 Study for Bat8006, an Antibody Drug Conjugate Targeting Folate Receptor A for the Treatment of Advanced Solid Tumors

Biogen Inc. and Bio-Thera Solutions, Ltd. Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate At the Annual European Congress of Rheumatology (EULAR 2022)

Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT7104, a Bispecific Antibody Targeting PD-L1 and CD47 for the Treatment of Advanced Solid Tumors

First quarter 2022 earnings released: CN¥0.27 loss per share (vs CN¥0.26 loss in 1Q 2021)

Bio-Thera Solutions, Ltd. Announces First Patient Dosed in Phase 1 Study in Australia Evaluating BAT6026, Anti-OX40 Antibody with Enhanced ADCC Effect, in Combination with BAT1308, Anti-PD-1 Antibody

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Bio-Thera Solutions, Ltd. Announces First Patient Dosed in Australia for BAT6021, ADCC-Enhanced Monoclonal Antibody Targeting TIGIT for Treatment of Solid Tumors

Bio-Thera Solutions Announces Initiation of Phase I Clinical Trials for BAT6005, a Monoclonal Antibody Targeting TIGIT

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS CN¥1.08 (vs CN¥0.34 loss in 2Q 2020)

Bio-Thera Solutions Announces First Patient Dosed in Phase III Clinical Trial for BAT2206

Bio-Thera Solutions Initiates Phase Iii Clinical Trial for Bat2506, A Proposed Biosimilar of Simponi® (Golimumab)

Biogen and Bio-Thera Announces Positive Results From Phase 3 Study of BAT1806

First quarter 2021 earnings released: CN¥0.26 loss per share (vs CN¥0.28 loss in 1Q 2020)

New 90-day low: CN¥25.00

Full year 2020 earnings released: CN¥1.27 loss per share (vs CN¥2.96 loss in FY 2019)

New 90-day low: CN¥25.03

Bio-Thera Solutions,Ltd. Announces FDA Accepts Biologics License Application for BAT1706, a Proposed Biosimilar to Avastin®

Bio-Thera Solutions, Ltd. Announces Initiation of Phase I Clinical Trial for BAT1308, a Monoclonal Antibody Targeting PD-1

Bio-Thera Solutions,Ltd. to Report Fiscal Year 2020 Results on Mar 05, 2021

New 90-day low: CN¥29.33

Bio-Thera Solutions Announces Licensing Agreement with Biomm S.A. to Distribute and Market BAT1706 in Brazil

New 90-day low: CN¥34.21

Bio-Thera Solutions,Ltd. Submits Marketing Authorization Application (MAA) for BAT1706, a Proposed Biosimilar to Avastin®, to European Medicines Agency (EMA)

New 90-day low: CN¥38.59

Bio-Thera Solutions,Ltd. to Report Q3, 2020 Results on Oct 30, 2020

New 90-day low: CN¥43.33

New 90-day low: CN¥43.73

New 90-day low - CN¥47.10

New 90-day low - CN¥47.90

Bio-Thera Solutions, Ltd. to Report First Half, 2020 Results on Aug 28, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin